388 related articles for article (PubMed ID: 30391013)
21. Stromal hyaluronan accumulation is associated with low tumor grade and nodal metastases in pancreatic ductal adenocarcinoma.
Larson BK; Guan M; Placencio V; Tuli R; Hendifar AE
Hum Pathol; 2019 Aug; 90():37-44. PubMed ID: 31121193
[TBL] [Abstract][Full Text] [Related]
22. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
23. Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers.
Koay EJ; Amer AM; Baio FE; Ondari AO; Fleming JB
Cancer Lett; 2016 Oct; 381(1):237-43. PubMed ID: 26806807
[TBL] [Abstract][Full Text] [Related]
24. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
Singh RR; O'Reilly EM
Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
[TBL] [Abstract][Full Text] [Related]
25. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
26. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
27. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.
Yu S; Zhang C; Xie KP
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188461. PubMed ID: 33157162
[TBL] [Abstract][Full Text] [Related]
29. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
Diab M; Azmi A; Mohammad R; Philip PA
Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
[TBL] [Abstract][Full Text] [Related]
30. Promising new therapies in advanced pancreatic adenocarcinomas.
Kundranda M; Kachaamy T
Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049
[TBL] [Abstract][Full Text] [Related]
31. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
32. Matrix control of pancreatic cancer: New insights into fibronectin signaling.
Topalovski M; Brekken RA
Cancer Lett; 2016 Oct; 381(1):252-8. PubMed ID: 26742464
[TBL] [Abstract][Full Text] [Related]
33. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A
Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232
[TBL] [Abstract][Full Text] [Related]
34. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS; Pellat A; Brezault C; Dhooge M; Coriat R
ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
[TBL] [Abstract][Full Text] [Related]
35. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.
Aslan M; Shahbazi R; Ulubayram K; Ozpolat B
Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367
[TBL] [Abstract][Full Text] [Related]
36. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer.
Duan K; Jang GH; Grant RC; Wilson JM; Notta F; O'Kane GM; Knox JJ; Gallinger S; Fischer S
Sci Rep; 2021 Jul; 11(1):14951. PubMed ID: 34294813
[TBL] [Abstract][Full Text] [Related]
37. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma.
Stubbe BE; Madsen PH; Larsen AC; Krarup HB; Pedersen IS; Hansen CP; Johansen JS; Henriksen SD; Thorlacius-Ussing O
Pancreatology; 2023 Aug; 23(5):512-521. PubMed ID: 37230892
[TBL] [Abstract][Full Text] [Related]
38. Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma.
Igbinigie E; Guo F; Jiang SW; Kelley C; Li J
Clin Chim Acta; 2019 Jan; 488():226-234. PubMed ID: 30452897
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
40. The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma.
Kudo D; Suto A; Hakamada K
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
